Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM. et al, (2015), Lancet Oncol, 16, 928 - 936
The next steps in improving the outcomes of advanced ovarian cancer.
Openshaw MR. et al, (2015), Womens Health (Lond), 11, 355 - 367
Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer.
Borley J. et al, (2015), BJOG, 122, 843 - 849
Risk of Ovarian Cancer Relapse score: a prognostic algorithm to predict relapse following treatment for advanced ovarian cancer.
Rizzuto I. et al, (2015), Int J Gynecol Cancer, 25, 416 - 422
Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation.
Hopkins TG. et al, (2015), Climacteric, 18, 94 - 98
Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer.
Blagden SP., (2015), Front Oncol, 5
OBESITY, PHYSICAL INACTIVITY AND SYMPTOMS AFTER OVARIAN CANCER TREATMENT: RESULTS FROM AN INTERNATIONAL INTERNET-BASED SURVEY
Webber K. et al, (2015), INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 25, 42 - 43
First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer.
Blagden S. et al, (2014), Clin Cancer Res, 20, 5908 - 5917
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
Slusarczyk M. et al, (2014), J Med Chem, 57, 1531 - 1542
Developing an objective marker to optimize patient selection and predict survival benefit in early-phase cancer trials.
Stavraka C. et al, (2014), Cancer, 120, 262 - 270
Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer
Blagden S. et al, (2014), EUROPEAN JOURNAL OF CANCER, 50, 7 - 7
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials.
Pinato DJ. et al, (2014), PLoS One, 9
NUC-1031: A novel ProTide that overcomes the key cancer resistance mechanisms associated with poor survival
Ghazaly EA. et al, (2014), CANCER RESEARCH, 74
The mRNA-binding protein LARP1 is a pro-survival factor that promotes tumourigenicity and chemotherapy resistance in ovarian cancer
Hopkins TG. et al, (2014), EUROPEAN JOURNAL OF CANCER, 50, S26 - S26
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.
Fotopoulou C. et al, (2014), Ann Oncol, 25, 160 - 165
Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies.
O'Cathail SM. et al, (2013), Int J Gynecol Cancer, 23, 1318 - 1325
Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer
Camarata M. et al, (2013), BMJ Case Reports
Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer.
Camarata M. et al, (2013), BMJ Case Rep, 2013